SCM
KALV

Sio Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Sio Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-683,819
Closed -$8.33M – 73
2025
Q3 		$8.33M Buy
+683,819
New +$9.45M 2.11% 16

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sio Capital Management's KALV Position: Q4 2025 in Review

Sio Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q4 2025, closing a stake of 683,819 shares — an estimated $8.33M sold.

Sio Capital Management first reported a position in KALV in Q3 2025 and held it in 1 quarter. The position peaked at $8.33M in Q3 2025. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

  • Sio Capital Management reported no remaining KalVista Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Sio Capital Management sold 683,819 KalVista Pharmaceuticals shares in Q4 2025, an estimated $8.33M.
  • Sio Capital Management first reported a position in KalVista Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Sio Capital Management's KalVista Pharmaceuticals position peaked at $8.33M in Q3 2025.
  • 161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on Sio Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.